10-Q: Astria Therapeutics Q3 2025: BioCryst Merger, Navenibart Progress

Astria Therapeutics reports increased net loss in Q3 2025, driven by R&D for Navenibart and STAR-0310, while progressing towards a BioCryst merger and securing a Japan licensing deal.

Summary

• Net loss increased to $98.4 million for the nine months ended September 30, 2025, compared to $68.6 million for the same period in 2024.
• Collaboration revenue of $0.7 million was recognized in Q3 2025 from the Kaken License Agreement, with no revenue in the prior year.
• Research and development expenses rose by 37% to $77.9 million for the nine months ended September 30, 2025, primarily due to advancements in navenibart and STAR-0310 programs.
• General and administrative expenses increased by 19% to $29.7 million, driven by company growth and legal fees related to the proposed merger.
• Cash, cash equivalents, and short-term investments totaled $227.7 million as of September 30, 2025, with an estimated cash runway into 2028, assuming a standalone entity.
• A proposed acquisition by BioCryst Pharmaceuticals, Inc. was announced on October 14, 2025, with an expected closing in the first quarter of 2026.
• Navenibart's ALPHA-ORBIT Phase 3 trial was initiated in February 2025, with top-line results anticipated in early 2027.
• Positive final data from the ALPHA-STAR Phase 1b/2 trial of navenibart were presented in November 2025, showing significant attack rate reduction and favorable tolerability.
• STAR-0310's Phase 1a trial showed positive initial results in September 2025, demonstrating a long half-life and broad cytokine suppression.

Sentiment

Score: 6

Explanation: The filing presents a mixed bag. While financial losses are increasing and the company still requires significant future funding, the clinical progress for both lead candidates (navenibart and STAR-0310) is positive, and the proposed merger with BioCryst offers a potential exit and stability for shareholders. The Kaken licensing deal also provides non-dilutive funding and validation. The merger introduces new risks but also a clear path forward.

Positives

• Initiation of the ALPHA-ORBIT Phase 3 clinical trial for navenibart in February 2025, a significant step towards potential registration for hereditary angioedema (HAE).
• Positive final results from the ALPHA-STAR Phase 1b/2 trial for navenibart, demonstrating 91-95% reduction in monthly HAE attack rate and favorable tolerability.
• Positive initial results from the ALPHA-SOLAR long-term open-label trial for navenibart, showing robust attack rate reduction and a favorable safety profile.
• Successful Kaken License Agreement for navenibart in Japan, including a $16.0 million upfront payment and potential for $16.0 million in commercialization and sales milestones, plus tiered royalties.
• Positive initial Phase 1a results for STAR-0310, indicating a longest-in-class half-life of 68 days and broad cytokine suppression, supporting potential every-six-month administration for atopic dermatitis (AD).
• Estimated cash, cash equivalents, and short-term investments of $227.7 million as of September 30, 2025, providing a cash runway into 2028 (assuming standalone operations).
• Proposed acquisition by BioCryst Pharmaceuticals, Inc. offers a clear path for the company and its shareholders, with a defined merger consideration.

Negatives

• Net loss significantly increased to $98.4 million for the nine months ended September 30, 2025, from $68.6 million in the prior year, indicating higher operational burn.
• Interest and investment income decreased by 36% to $8.5 million for the nine months ended September 30, 2025, due to decreased interest-earning assets and lower yields.
• The company has an accumulated deficit of $773.2 million as of September 30, 2025, and has not generated any product revenues.
• Existing capital is not sufficient to fund the completion of development for any product candidates, necessitating substantial additional funding.
• Increased R&D and G&A expenses contribute to higher operating losses.

Risks

• The proposed acquisition by BioCryst may not be completed within the anticipated timeframe or at all, which could adversely affect the business, financial results, and operations.
• A termination fee of $32.25 million would be payable to BioCryst if the Merger Agreement is terminated under specific circumstances (e.g., Astria accepting a superior proposal or board changing recommendation).
• Stockholder lawsuits related to the merger could prevent or delay completion, divert management attention, and incur significant costs.
• The value of the merger consideration (BioCryst common stock) will fluctuate with BioCryst's market price, and stockholders will not know the exact value at the time of voting.
• Astria stockholders will have a significantly lower ownership and voting interest in BioCryst, exercising less influence over management.
• The aggregate number of BioCryst shares issued in the merger is capped at 19.9% of BioCryst's outstanding shares, potentially reducing the stock portion of the consideration and increasing the cash portion at a fixed valuation.
• The business is almost entirely dependent on the success of navenibart and STAR-0310, which are in early to mid-stage clinical development.
• Substantial additional funding will be required to complete development and commercialization of product candidates and support future operations, which may not be available on acceptable terms or at all.
• The Kaken License Agreement and any future collaborations may not lead to successful development, regulatory approval, or commercialization, and collaborators may have competing priorities or terminate agreements.
• Disruptions at the FDA and other government agencies (e.g., funding cuts, personnel losses, government shutdowns, regulatory reform) could negatively impact development timelines and approval processes.
• Changes in U.S. trade policy, including tariffs, could increase costs for raw materials, cause supply chain disruptions, and delay product development, especially given reliance on third-party manufacturers outside the U.S.

Future Outlook

The company anticipates top-line results from the ALPHA-ORBIT Phase 3 trial of navenibart in early 2027. It expects to fund operating expenses and capital expenditure requirements into 2028, assuming it remains a standalone entity and without giving effect to the proposed merger. The current operating plan includes supporting all navenibart program activities through the completion of the ALPHA-ORBIT Phase 3 trial, including ORBIT-EXPANSE and drug device combination development, and completing the ongoing Phase 1a clinical trial for STAR-0310. The company will require substantial additional funding to complete the development and commercialization of its product candidates and expand its pipeline.

Management Comments

• "Our vision for navenibart is to lead the HAE market and become the first-choice preventative treatment for HAE with administration every three and six months with the goal of normalizing the lives of people living with HAE."
• "We believe that with both of these programs [navenibart and STAR-0310], we are advancing a pipeline of products with meaningfully differentiated profiles based on validated mechanisms."
• "Our goal for STAR-0310 is to reduce disease activity, relapse rate, and treatment burden for patients with moderate-to-severe AD."
• "Following recent positive Phase 1a initial results, we are exploring strategic opportunities for STAR-0310."
• Chris Morabito, Chief Medical Officer, terminated a Rule 10b5-1 trading arrangement for the sale of common stock on September 25, 2024.

Industry Context

The HAE treatment landscape has improved, but significant unmet medical need remains, and the global market for HAE therapy is strong and growing. Navenibart aims to be a best-in-class, long-acting preventative treatment. For atopic dermatitis (AD), current treatment options are insufficient, and STAR-0310 seeks to address the need for a safe, effective, and infrequently administered treatment, potentially competing with first-generation OX40 antibodies.

Comparison to Industry Standards

• Navenibart is positioned as a "potential best-in-class" and "market-leading and most patient-friendly chronic treatment option" for HAE, based on its proof-of-concept data and the existing HAE treatment landscape.
• STAR-0310 exhibited a "longest-in-class half-life of 68 days" and "broad cytokine suppression lasting at least 20 weeks" after a single 300 mg SC injection, supporting potential every-six-month administration, which is a key differentiator compared to other OX40 antagonists.
• STAR-0310's profile supports a "wider therapeutic window with the potential to drive greater efficacy than first-generation OX40 antibodies."

Legal Proceedings

• Potential stockholder litigation against the company, BioCryst, and/or their directors and officers in connection with the merger.

Stakeholder Impact

• Shareholders: Will receive BioCryst common stock and cash if the merger closes, but face uncertainty regarding the merger's completion and potential fluctuations in BioCryst's stock price. Future capital raises could dilute ownership.
• Employees: May experience uncertainty about their roles following the consummation of the merger.
• Patients (HAE & AD): Potential for new, differentiated treatment options (navenibart and STAR-0310) if development and commercialization are successful.
• Kaken Pharmaceutical Co., Ltd.: Will develop and commercialize navenibart in Japan, supporting the global Phase 3 trial.

Next Steps

• Closing of the proposed merger with BioCryst Pharmaceuticals, Inc. in the first quarter of 2026.
• Release of top-line results from the ALPHA-ORBIT Phase 3 trial of navenibart in early 2027.
• Continued enrollment in the ORBIT-EXPANSE long-term trial for navenibart.
• Continued development and testing of autoinjector and pre-filled syringe drug device combinations for navenibart.
• Completion of the ongoing Phase 1a clinical trial of STAR-0310 in healthy subjects.
• Exploring strategic opportunities for STAR-0310.
• Kaken Pharmaceutical Co., Ltd. to provide support for the ALPHA-ORBIT Phase 3 trial in Japan and be responsible for regulatory submissions in Japan.

Key Dates

Recommendation

The proposed merger with BioCryst Pharmaceuticals provides a defined valuation and a clear path forward for Astria, reducing standalone operational risks. However, the merger is not yet complete and carries inherent risks, including potential termination or changes to the consideration. While clinical data for navenibart and STAR-0310 are promising, the company continues to incur significant losses and requires substantial future funding if the merger does not proceed or if it were to remain a standalone entity. The current financial position and clinical progress are positive, but the uncertainty surrounding the merger's completion and the long-term funding needs warrant a 'hold' recommendation until the merger is finalized or a clearer standalone strategy emerges.

Keywords

Astria Therapeutics, BioCryst Pharmaceuticals, Merger Agreement, Navenibart, Hereditary Angioedema, HAE, STAR-0310, Atopic Dermatitis, AD, Clinical Trials, Phase 3, ALPHA-ORBIT, ALPHA-STAR, ALPHA-SOLAR, Kaken Pharmaceutical, License Agreement, Biopharmaceutical, Drug Development, SEC Filing, 10-Q, Financial Results, Cash Runway, Regulatory Approval, Orphan Drug, Fast Track